The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Fabry disease: overall effects of agalsidase alfa treatment
Abstract
Background Fabry disease is a rare X‐linked disorder caused by deficient activity of the lysosomal enzyme α‐galactosidase A. Progressive accumulation of the substrate globotriaosylceramide in cells throughout the body leads to major organ failure and premature death. The Fabry Outcome Survey (FOS) is a European outcomes database which was established to collect data on the natural history of this little‐known disease and to monitor the long‐term efficacy and safety of enzyme replacement therapy (ERT) with agalsidase alfa. This paper presents the first analysis of the FOS database on the effects of ERT on renal function, heart size, pain and quality of life. Design The effects of 1 and 2 years of ERT with agalsidase alfa on renal function (assessed by estimated glomerular filtration rate), heart size (assessed by echocardiography), pain (assessed by the Brief Pain Inventory) and quality of life (assessed by the European Quality of Life Questionnaire EQ‐5D) were analyzed in a cohort of 545 patients, 314 of whom were receiving treatment (188 for at least 12 months and 92 for at least 24 months; mean duration of treatment, 17 months; maximum duration, 56 months). Results Treatment with agalsidase alfa stabilized renal function in patients with a mild or moderate deterioration in renal function at baseline, reduced left ventricular size in patients who had an enlarged heart at baseline, and improved pain scores and quality of life. These improvements were similar in hemizygous men and heterozygous women with Fabry disease. Conclusions Enzyme replacement therapy with agalsidase alfa leads to significant clinical benefits in patients with Fabry disease, and treatment is likely to alter the natural history of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Zarate, Y. A., & Hopkin, R. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61589-5 · Cited by 795
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Feldt-Rasmussen, U., Sims, K., Waldek, S., Pastores, G. M., Lee, P., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.09.013 · Cited by 544
Weidemann, F., Niemann, M., Breunig, F., Herrmann, S., Beer, M., Störk, S., Voelker, W., Ertl, G., Wanner, C., & Strotmann, J. (2009) · Circulation · doi:10.1161/circulationaha.108.794529 · Cited by 488
Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.205 · Cited by 412
Metadata
- Authors
- Beck, M., Ricci, R., Widmer, U., Dehout, F., De Lorenzo, A. G., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Houge, G., Ramaswami, U., Gal, A., & Mehta, A.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 34
- Issue
- 12
- Pages
- 838-844
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W2154062927
- Cited by
- 224
- References
- 1
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fabry disease: overall effects of agalsidase alfa treatment. https://app.cochat.ai/papers/10.1111/j.1365-2362.2004.01424.x
- The paper
- Beck, M., Ricci, R., Widmer, U., Dehout, F., De Lorenzo, A. G., Kampmann, C., Linhart, A., Sunder‐Plassmann, G., Houge, G., Ramaswami, U., Gal, A., & Mehta, A. (2004). Fabry disease: overall effects of agalsidase alfa treatment. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2004.01424.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.